WO2011017488A3 - Combinaison d'un modulateur ppar-gamma sélectif et d'une incrétine pour le traitement du diabète et de l'obésité - Google Patents

Combinaison d'un modulateur ppar-gamma sélectif et d'une incrétine pour le traitement du diabète et de l'obésité Download PDF

Info

Publication number
WO2011017488A3
WO2011017488A3 PCT/US2010/044495 US2010044495W WO2011017488A3 WO 2011017488 A3 WO2011017488 A3 WO 2011017488A3 US 2010044495 W US2010044495 W US 2010044495W WO 2011017488 A3 WO2011017488 A3 WO 2011017488A3
Authority
WO
WIPO (PCT)
Prior art keywords
incretin
obesity
diabetes
combination
treatment
Prior art date
Application number
PCT/US2010/044495
Other languages
English (en)
Other versions
WO2011017488A2 (fr
Inventor
Dennis Lanfear
Linda Higgins
Original Assignee
Intekrin Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intekrin Therapeutics, Inc. filed Critical Intekrin Therapeutics, Inc.
Publication of WO2011017488A2 publication Critical patent/WO2011017488A2/fr
Publication of WO2011017488A3 publication Critical patent/WO2011017488A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques et des procédés pour le traitement du diabète, de l'obésité ou de troubles associés au diabète ou à l'obésité. Les compositions comprennent une combinaison d'un modulateur PPARγ sélectif et d'une incrétine. Les procédés comprennent l'administration de la combinaison d'un modulateur PPARγ sélectif et d'une incrétine.
PCT/US2010/044495 2009-08-05 2010-08-05 Combinaison d’un modulateur ppar-gamma sélectif et d’une incrétine pour le traitement du diabète et de l’obésité WO2011017488A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23149909P 2009-08-05 2009-08-05
US61/231,499 2009-08-05

Publications (2)

Publication Number Publication Date
WO2011017488A2 WO2011017488A2 (fr) 2011-02-10
WO2011017488A3 true WO2011017488A3 (fr) 2011-07-07

Family

ID=43535272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/044495 WO2011017488A2 (fr) 2009-08-05 2010-08-05 Combinaison d’un modulateur ppar-gamma sélectif et d’une incrétine pour le traitement du diabète et de l’obésité

Country Status (2)

Country Link
US (1) US20110034380A1 (fr)
WO (1) WO2011017488A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040082A2 (fr) * 2010-09-21 2012-03-29 Intekrin Therapeutics, Inc. Compositions pharmaceutiques solides antidiabétiques
MX2017011586A (es) 2015-03-09 2017-10-26 Intekrin Therapeutics Inc Metodos para el tratamiento de enfermedad de higado graso no alcoholico y/o lipodistrofia.
MX2019011867A (es) 2017-04-03 2020-01-09 Coherus Biosciences Inc Agonista de ppary para el tratamiento de la paralisis supranuclear progresiva.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033074A2 (fr) * 2003-10-03 2005-04-14 Amgen, Inc. Sels et polymorphes de compose antidiabetique puissant

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080132555A1 (en) * 2006-11-28 2008-06-05 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted phenyltetrazoles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033074A2 (fr) * 2003-10-03 2005-04-14 Amgen, Inc. Sels et polymorphes de compose antidiabetique puissant

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARULMOZHI, D.K. ET AL.: "GLP-1 based therapy for type 2 diabetes.", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES., vol. 28, 2006, pages 96 - 108, XP025137306, DOI: doi:10.1016/j.ejps.2006.01.003 *
CHIA, C.W. ET AL.: "Incretin-based therapies in type 2 diabetes mellitus.", THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 93, no. 10, 2008, pages 3703 - 3716, XP055080684, DOI: doi:10.1210/jc.2007-2109 *

Also Published As

Publication number Publication date
WO2011017488A2 (fr) 2011-02-10
US20110034380A1 (en) 2011-02-10

Similar Documents

Publication Publication Date Title
WO2011130302A3 (fr) Procédés de traitement de l'obésité utilisant des modulateurs d'inflammation antioxydants
WO2011140202A3 (fr) Modulateurs de mif
WO2010123930A3 (fr) Thérapies à base de ligand de récepteur chimiosensible
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
WO2007104789A3 (fr) Dérivés d'amyline
WO2009089494A3 (fr) Compositions pharmaceutiques
WO2011103202A3 (fr) Modulateurs du récepteur des androgènes et leurs utilisations
WO2012037411A3 (fr) Modulateurs des récepteurs des oestrogènes et leurs utilisations
WO2011156518A3 (fr) Modulateur du récepteur oestrogénique et utilisation de ces derniers
WO2010021693A3 (fr) Modulateurs de mif
IN2012DN02469A (fr)
WO2011159769A3 (fr) Modulateurs de récepteur d'œstrogène d'indane et utilisations de ceux-ci
WO2010127099A3 (fr) Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
WO2009129246A3 (fr) Compositions et leurs procédés de préparation et d'utilisation
WO2011055215A3 (fr) Nouveaux modulateurs de kinase
WO2010008831A3 (fr) Composés et procédés pour moduler les récepteurs couplés à la protéine g
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
WO2011086093A3 (fr) Compositions pharmaceutiques pour l'administration orale de peptides de l'insuline
WO2011090270A3 (fr) Composition contenant de l'osmotine pour prévenir et traiter des troubles neurologiques
AP2013006985A0 (en) Fused dihydrofurans as GPR119 modulators for the treatment of diabetes, obesity and related disorders
WO2009089234A3 (fr) Dibenzhydrylpipérazines substituées
WO2010147830A3 (fr) Modulateurs aminothiazole de bêta-3-adrénorécepteur
WO2011090694A8 (fr) Formes pharmaceutiques se présentant sous la forme de films administrables par voie orale contenant de l'ondansétron
WO2011072069A3 (fr) Compositions pharmaceutiques à temps de résidence gastrique augmenté utilisées pour une libération prolongée de polypeptides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10807135

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 13.04.2012)

122 Ep: pct application non-entry in european phase

Ref document number: 10807135

Country of ref document: EP

Kind code of ref document: A2